Long-term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population.

MLA

Nordestgaard, Liv Tybjærg, et al. “Long-Term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population.” JAMA Cardiology, vol. 7, no. 1, Jan. 2022, pp. 55–64. EBSCOhost, https://doi.org/10.1001/jamacardio.2021.3728.

APA

Nordestgaard, L. T., Christoffersen, M., Lauridsen, B. K., Afzal, S., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A. (2022). Long-term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population. JAMA Cardiology, 7(1), 55–64. https://doi.org/10.1001/jamacardio.2021.3728

Chicago

Nordestgaard, Liv Tybjærg, Mette Christoffersen, Bo Kobberø Lauridsen, Shoaib Afzal, Børge Grønne Nordestgaard, Ruth Frikke-Schmidt, and Anne Tybjærg-Hansen. 2022. “Long-Term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population.” JAMA Cardiology 7 (1): 55–64. doi:10.1001/jamacardio.2021.3728.